Quadriga BioSciences

Executive Summary

Quadriga BioSciences is a San Diego-based biotechnology company founded in 2018, focused on developing novel small molecule therapeutics that exploit amino acid transporters to deliver chemotherapeutic agents selectively into cancer cells, including across the blood-brain barrier. Its lead program, QBS72S, is a first-in-class 'Trojan Horse' chemotherapeutic designed to overcome resistance and improve efficacy in solid tumors, particularly those with brain metastases. The company leverages a proprietary platform targeting the LAT1 transporter, which is overexpressed on many cancer types. Quadriga is currently advancing QBS72S toward clinical development, with preclinical data suggesting a favorable safety profile and potent anti-tumor activity. As a private, early-stage biotech, Quadriga's success hinges on successful IND filing and initial clinical results, which could position it as a leader in transporter-mediated drug delivery for oncology.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for QBS72S70% success
• TBDPhase 1 Trial Initiation60% success
• Q3 2026Preclinical Data Presentation at Major Conference80% success